CME Group Inc. (NASDAQ:CME) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a note issued to investors on Monday. They currently have a $116.00 price target on the stock. JPMorgan Chase & Co.’s price objective indicates a potential downside of 0.06% from the company’s current price. The analysts noted that the move was a valuation call.

Other equities research analysts have also issued reports about the stock. Keefe, Bruyette & Woods raised their price target on shares of CME Group from $99.00 to $103.00 and gave the company a “market perform” rating in a report on Friday, July 29th. Deutsche Bank AG raised their price target on shares of CME Group from $111.00 to $112.00 and gave the company a “buy” rating in a report on Friday, August 5th. Barclays PLC lowered their price target on shares of CME Group from $100.00 to $99.00 and set an “equal weight” rating for the company in a report on Friday, July 29th. Zacks Investment Research raised shares of CME Group from a “hold” rating to a “buy” rating and set a $116.00 price target for the company in a report on Thursday, August 4th. Finally, RBC Capital Markets set a $92.00 price target on shares of CME Group and gave the company a “sell” rating in a report on Friday, October 28th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. CME Group currently has an average rating of “Hold” and a consensus price target of $102.89.

Analyst Recommendations for CME Group (NASDAQ:CME)

Shares of CME Group (NASDAQ:CME) opened at 116.07 on Monday. The stock has a market capitalization of $39.39 billion, a PE ratio of 27.06 and a beta of 0.81. CME Group has a one year low of $81.87 and a one year high of $117.80. The stock has a 50 day moving average of $105.13 and a 200-day moving average of $101.77.

CME Group (NASDAQ:CME) last issued its earnings results on Thursday, October 27th. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.04 by $0.01. CME Group had a net margin of 41.54% and a return on equity of 6.90%. The business had revenue of $842 million for the quarter, compared to the consensus estimate of $855.94 million. During the same quarter last year, the firm posted $1.02 EPS. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. Equities analysts predict that CME Group will post $4.35 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 28th. Investors of record on Friday, December 9th will be given a $0.60 dividend. The ex-dividend date is Wednesday, December 7th. This represents a $2.40 annualized dividend and a yield of 2.07%. CME Group’s dividend payout ratio is presently 55.94%.

In other CME Group news, CEO Phupinder Gill sold 30,002 shares of the business’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $110.00, for a total transaction of $3,300,220.00. Following the sale, the chief executive officer now directly owns 116,222 shares in the company, valued at approximately $12,784,420. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Martin J. Gepsman sold 300 shares of the business’s stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $109.00, for a total transaction of $32,700.00. Following the sale, the director now owns 42,802 shares in the company, valued at $4,665,418. The disclosure for this sale can be found here. 0.61% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in CME. Hudock Capital Group LLC increased its stake in CME Group by 0.5% in the third quarter. Hudock Capital Group LLC now owns 3,726 shares of the company’s stock worth $389,000 after buying an additional 20 shares during the period. Windward Capital Management Co. CA boosted its position in shares of CME Group by 1.0% in the second quarter. Windward Capital Management Co. CA now owns 2,626 shares of the company’s stock valued at $256,000 after buying an additional 25 shares in the last quarter. Gofen & Glossberg LLC IL boosted its position in shares of CME Group by 0.4% in the second quarter. Gofen & Glossberg LLC IL now owns 7,323 shares of the company’s stock valued at $713,000 after buying an additional 26 shares in the last quarter. Beacon Financial Group boosted its position in shares of CME Group by 0.8% in the second quarter. Beacon Financial Group now owns 4,525 shares of the company’s stock valued at $435,000 after buying an additional 38 shares in the last quarter. Finally, Pekin Singer Strauss Asset Management IL boosted its position in shares of CME Group by 0.3% in the second quarter. Pekin Singer Strauss Asset Management IL now owns 13,811 shares of the company’s stock valued at $1,345,000 after buying an additional 39 shares in the last quarter. Institutional investors own 80.60% of the company’s stock.

CME Group Company Profile

CME Group Inc is a provider of products across all major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. The Company’s products include both exchange-traded and privately negotiated futures and options contracts and swaps. The Company connects buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City.

5 Day Chart for NASDAQ:CME

Receive News & Stock Ratings for CME Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group Inc. and related stocks with our FREE daily email newsletter.